Indication name: Ornithine
Transcarbamylase (OTC) Deficiency
Ornithine
Transcarbamylase (OTC) Deficiency – Market outlook, Epidemiology, Market
Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US,
Germany, France, Spain, United Kingdom, Italy, Japan & China)
Ornithine Transcarbamylase (OTC)
Deficiency - OTC
is a mitochondrial matrix enzyme and catalyzes the condensation of
carbamoylphosphate and ornithine to form citrulline. The gene encoding OTC is
at Xp21.1. Patients with OTC deficiency, like other inborn errors of
metabolism, represent a range of disease severity correlating with the degree
of residual enzymatic function. Ornithine transcarbamylase deficiency (OTCD),
an X-linked disorder, is the most common urea cycle disorder (UCD).
Epidemiology-
According to Thelansis disease modeling data, results of literature reviews,
surveys, and registry analyses, the estimated incidence rate is 1/17 000 in the
USA.
Competitive landscape of Ornithine Transcarbamylase (OTC) Deficiency includes
country specific approved as well as pipeline therapies. Any asset/ product
specific designation or review and Accelerated Approval are being tracked and
supplemented with analyst commentary.
KOLs insights of Ornithine Transcarbamylase (OTC) Deficiency8 MM market from
center of Excellence/ Public/ Private hospitals participated in the study.
Insights around current treatment landscape, epidemiology, clinical
characteristics, future treatment paradigm and Unmet needs.
Ornithine Transcarbamylase (OTC) Deficiency market forecast: Patient Based
Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with
sourcing, Market Event and Product Event, Country specific Forecast Model,
Market uptake and patient share uptake, Attribute Analysis, Analog Analysis,
Disease burden and pricing scenario, Summary and Insights.
Read more: Ornithine Transcarbamylase (OTC)
Deficiency – Market outlook, Epidemiology, Market Forecast and Competitive
Landscape Report – 2020 To 2030
S. No Asset Company Stage
1 ARCT-810 Arcturus Therapeutics, Inc. Phase 2
2 scAAV8OTC Ultragenyx Pharmaceutical Inc Phase 2
3 Human Heterologous Liver Cells Cytonet GmbH & Co. KG Phase 2
4 KB195 Kaleido Biosciences Phase 2
No comments:
Post a Comment